Document detail
ID

oai:HAL:hal-03949602v1

Topic
Adults Air pollution Long-term exposure Low-level exposure Parkinson's Disease Pooled-cohort study [SDV]Life Sciences [q-bio]
Author
Cole-Hunter, Tom Zhang, Jiawei So, Rina Samoli, E. Liu, Shuo Chen, Jie Strak, Maciej Wolf, Kathrin Weinmayr, Gudrun Rodopolou, Sophia Remfry, Elizabeth de Hoogh, Kees Bellander, Tom D. Brandt, Jørgen Concin, H. Zitt, Emanuel Fecht, Daniela Forastiere, Francesco Gulliver, John Hoffmann, Barbara H. Hvidtfeldt, Ulla Arthur Jöckel, Karl Heinz Mortensen, Laust H. Ketzel, Matthias Yacamán Méndez, Diego Leander, Karin Ljungman, Petter L.S. Faure, Élodie Lee, Peichen Elbaz, Alexis Magnusson, Patrik Karl Erik Nagel, Gabriele Pershagen, Göran Peters, Annette Rizzuto, Debora Vermeulen, Roel C.H. Schramm, Sara Helena Stafoggia, Massimo Katsouyanni, K. Brunekreef, Bert Hoek, Gerard Lim, Younhee Andersen, Zorana
Langue
en
Editor

HAL CCSD;Elsevier

Category

sciences: life sciences

Year

2023

listing date

12/15/2023

Keywords
parkinson µg/m3 disease study european associations exposure 0 air pollution long-term pm2 pd no2 mortality
Metrics

Abstract

International audience; Background: The link between exposure to ambient air pollution and mortality from cardiorespiratory diseases is well established, while evidence on neurodegenerative disorders including Parkinson's Disease (PD) remains limited.

Objective: We examined the association between long-term exposure to ambient air pollution and PD mortality in seven European cohorts.

Methods: Within the project ‘Effects of Low-Level Air Pollution: A Study in Europe’ (ELAPSE), we pooled data from seven cohorts among six European countries.

Annual mean residential concentrations of fine particulate matter (PM2.5), nitrogen dioxide (NO2), black carbon (BC), and ozone (O3), as well as 8 PM2.5 components (copper, iron, potassium, nickel, sulphur, silicon, vanadium, zinc), for 2010 were estimated using Europe-wide hybrid land use regression models.

PD mortality was defined as underlying cause of death being either PD, secondary Parkinsonism, or dementia in PD.

We applied Cox proportional hazard models to investigate the associations between air pollution and PD mortality, adjusting for potential confounders.

Results: Of 271,720 cohort participants, 381 died from PD during 19.7 years of follow-up.

In single-pollutant analyses, we observed positive associations between PD mortality and PM2.5 (hazard ratio per 5 µg/m3: 1.25; 95% confidence interval: 1.01–1.55), NO2 (1.13; 0.95–1.34 per 10 µg/m3), and BC (1.12; 0.94–1.34 per 0.5 × 10-5m-1), and a negative association with O3 (0.74; 0.58–0.94 per 10 µg/m3).

Associations of PM2.5, NO2, and BC with PD mortality were linear without apparent lower thresholds.

In two-pollutant models, associations with PM2.5 remained robust when adjusted for NO2 (1.24; 0.95–1.62) or BC (1.28; 0.96–1.71), whereas associations with NO2 or BC attenuated to null.

O3 associations remained negative, but no longer statistically significant in models with PM2.5.

We detected suggestive positive associations with the potassium component of PM2.5.

Conclusion: Long-term exposure to PM2.5, at levels well below current EU air pollution limit values, may contribute to PD mortality.

Cole-Hunter, Tom,Zhang, Jiawei,So, Rina,Samoli, E.,Liu, Shuo,Chen, Jie,Strak, Maciej,Wolf, Kathrin,Weinmayr, Gudrun,Rodopolou, Sophia,Remfry, Elizabeth,de Hoogh, Kees,Bellander, Tom D.,Brandt, Jørgen,Concin, H.,Zitt, Emanuel,Fecht, Daniela,Forastiere, Francesco,Gulliver, John,Hoffmann, Barbara H.,Hvidtfeldt, Ulla Arthur,Jöckel, Karl Heinz,Mortensen, Laust H.,Ketzel, Matthias,Yacamán Méndez, Diego,Leander, Karin,Ljungman, Petter L.S.,Faure, Élodie,Lee, Peichen,Elbaz, Alexis,Magnusson, Patrik Karl Erik,Nagel, Gabriele,Pershagen, Göran,Peters, Annette,Rizzuto, Debora,Vermeulen, Roel C.H.,Schramm, Sara Helena,Stafoggia, Massimo,Katsouyanni, K.,Brunekreef, Bert,Hoek, Gerard,Lim, Younhee,Andersen, Zorana, 2023, Long-term air pollution exposure and Parkinson's disease mortality in a large pooled European cohort: An ELAPSE study, HAL CCSD;Elsevier

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw